ArticleMarine biotechnology (New York, N.Y.)2026
Isolation, Characterization, and Biological Significance of a Novel C-type Marine Lectin Purified from Scylla serrata Hemolymph.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine lectins are unique glycoproteins that induce non-specific immunity in fishes and crustaceans. Mud crab Scylla serrata (S. serrata) is of significant economic value and is widely distributed, though it is considered a prized species in Southeast Asian countries. However, the characterisation of the C-type specific lectins is still not explored properly. In this current study, a novel C-type lectin (Ss-Lec) was purified from the hemolymph of the mud crab S. serrata, revealing a 71 kDa protein with remarkable biochemical and functional diversity. The purified Ss-Lec displayed a single sharp X-ray diffraction (XRD ) peak at 31.7°, a distinct High-performance liquid chromatography (HPLC) retention time of 5.259 min, and characteristic Fourier Transform Infrared (FTIR) and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) profiles, confirming its high purity and structural integrity. Functionally, Ss-Lec exhibited strong hemagglutination activity at physiological pH (7-8) and moderate temperature (30 °C), with calcium dependence verified by EDTA (Ethylenediaminetetraacetic acid) inhibition. The lectin effectively agglutinated human erythrocytes and Saccharomyces cerevisiae, with activity specifically inhibited by N-acetylglucosamine, D-mannose, and fucose. Beyond its agglutination potential, Ss-Lec significantly enhanced cellular encapsulation and phenoloxidase activity, underscoring its immunomodulatory capacity. Notably, Ss-Lec demonstrated potent antibacterial activity against major aquatic pathogens, forming inhibition zones up to 7 mm, and exhibited robust antibiofilm effectsachieving 82% inhibition against Edwardsiella tarda and over 68% against other tested species. Collectively, these findings reveal Ss-Lec as a multifunctional immune lectin with promising antimicrobial and antibiofilm properties, highlighting its potential role in crustacean immunity and its future application as a natural bioactive molecule in aquaculture health management.
Indexed as
Identifiers
42429879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.